ClinicalTrials.gg
CompletedNCT00440661Updated Mar 4, 2010

Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis

A Phase 4 interventional study of Diacerhein in Osteoarthritis, sponsored by Laboratoires NEGMA. Completed at 1 site in Canada. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-03-04.

Sponsored by Laboratoires NEGMA (part of Wockhardt) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.

Planned enrollment
90th of 176
96 · median 98
Started
2007
with 10 others
Phase 4
13 of 205
1 open now
Registered
21st of 205
by date

Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 90th largest by planned enrollment of the 176 interventional ones that give a count, is one of 11 that started in 2007, is one of 13 in phase 4, and was the 21st registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Osteoarthritis with a site in Canada, or all of them as a file.
02

Study summary

Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis, IL-1
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Painful osteoarthritis
  • Hydarthrosis (synovial effusion)

Exclusion criteria

Exclusion Criteria:

  • large effusion
  • severe pathologies
  • anti-osteoarthritic treatments
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
96 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Synovial concentration of IL-1

Secondary outcomes

  1. Synovial concentration of IL-6

  2. WOMAC

07

Study locations

1 site
  • Rheumatologic Institut of Montreal
    Montreal, Quebec H2L1S6, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2007
First posted
Feb 27, 2007
Start
Mar 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Mar 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00440661
Lead sponsor
Laboratoires NEGMA
First posted
Feb 27, 2007
Start date
Mar 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Mar 4, 2010

Study contacts

Jean-Pierre RAYNAULD, MD
principal investigator · Institut de Rhumatologie de Montreal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion